A phase 1, 2-part, randomized, subject and investigator blinded, placebo-controlled, cross-over trial to evaluate the safety, tolerability and pharmacokinetics Of CE-326,597 in obese, adult subjects with asymptomatic cholelithiasis.
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2010
At a glance
- Drugs CE 326597 (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacokinetics
- 14 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Oct 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Jan 2008 Status changed from initiated to recruiting.